The findings from The Cancer Immunome Atlas (TCIA) align with this correlation, demonstrating that when at least one of CTLA-4 or PD-1 is positive, high expression of EVI2A is associated with increased sensitivity to immunotherapy. The gene discussed is CTLA4; the disease is cancer.